Antithrombotic therapy represents the cornerstone of the pharmacological treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) to reduce the risk of ischemic recurrences. However, more intensified antithrombotic treatment is unavoidably associated with an increased hazard of bleeding events.
In the last decade, improvements in devices and PCI techniques have reduced the risk of ischemic events. Therefore, among ACS patients without clinical indication for oral anticoagulation, different antithrombotic strategies have been tested against standard (12-month) dual antiplatelet therapy (DAPT) consisting of either shortening the duration of DAPT or selecting the type of single antiplatelet therapy (aspirin versus P2Y12 inhibitor) after a short DAPT course according to the ischemic and bleeding risk.
This Research Topic focuses on the individualization of antithrombotic treatment for patients with ACS undergoing PCI according to the bleeding and ischemic risk. Moreover, since the optimal treatment may change over time due to new-onset comorbidities or clinical events (re-PCI, bleeding, stroke), the differentiation of treatment according to the time from the index event and the balance of ischemic versus bleeding risk remains key for a tailored antithrombotic approach.
The Topic Editors welcome manuscripts within this area of research, with the aim of giving the reader an overview of the latest findings coming from randomized trials, showing new findings on the topic and, finally, guiding the clinicians in their decision-making process of which therapy, for how long, and for what patient.
Among others, this Research Topic will focus on the following sub-themes:
• Antithrombotic treatment strategies in patients with high bleeding risk
• De-escalation of antiplatelet therapy
• Abbreviated antiplatelet therapy
• Long-term antithrombotic therapy for ACS patients: aspirin or P2Y12 inhibitors?
• Risk scores for guiding antithrombotic therapy
Antithrombotic therapy represents the cornerstone of the pharmacological treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) to reduce the risk of ischemic recurrences. However, more intensified antithrombotic treatment is unavoidably associated with an increased hazard of bleeding events.
In the last decade, improvements in devices and PCI techniques have reduced the risk of ischemic events. Therefore, among ACS patients without clinical indication for oral anticoagulation, different antithrombotic strategies have been tested against standard (12-month) dual antiplatelet therapy (DAPT) consisting of either shortening the duration of DAPT or selecting the type of single antiplatelet therapy (aspirin versus P2Y12 inhibitor) after a short DAPT course according to the ischemic and bleeding risk.
This Research Topic focuses on the individualization of antithrombotic treatment for patients with ACS undergoing PCI according to the bleeding and ischemic risk. Moreover, since the optimal treatment may change over time due to new-onset comorbidities or clinical events (re-PCI, bleeding, stroke), the differentiation of treatment according to the time from the index event and the balance of ischemic versus bleeding risk remains key for a tailored antithrombotic approach.
The Topic Editors welcome manuscripts within this area of research, with the aim of giving the reader an overview of the latest findings coming from randomized trials, showing new findings on the topic and, finally, guiding the clinicians in their decision-making process of which therapy, for how long, and for what patient.
Among others, this Research Topic will focus on the following sub-themes:
• Antithrombotic treatment strategies in patients with high bleeding risk
• De-escalation of antiplatelet therapy
• Abbreviated antiplatelet therapy
• Long-term antithrombotic therapy for ACS patients: aspirin or P2Y12 inhibitors?
• Risk scores for guiding antithrombotic therapy
